Follows adults with psoriatic arthritis treated with risankizumab over time
Observes how long adults with psoriatic arthritis stay on risankizumab compared with other treatments.
Key facts
- Who runs it
- AbbVie
- Where
- Granada, Huelva, Lorca, Madrid, Málaga, Murcia, Seville, and Vigo, SpainSee the 11 sitesAlso in 14 other countries, 121 sites
- Trial code
- Registry title
- An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
- Status
- Recruiting
- People taking part
- 1,200 people, planned
- Started
- 31 Jan 2025
- Expected to end
- Feb 2029
- Type of study
- Observational, 2 groups
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active psoriatic arthritis who did not respond well to, or could not take, at least 1 standard arthritis drug (DMARD).
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Psoriatic arthritis diagnosed by a doctor, with symptoms starting at least 6 months before screening and active disease confirmed at the Baseline visit.
- Earlier treatment
- Inadequate response to at least 1 DMARD (at most 50% of participants may have had an inadequate response to a biologic DMARD), or intolerance of or a contraindication to csDMARDs as judged by the investigator.
Main reasons for not taking part
- Inadequate response to three or more bDMARDs or targeted synthetic DMARDs (tsDMARDs)
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease
- Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator
Who cannot take part
- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Spain
Also in 14 other countries, 121 sites
- Hospital Universitario Clinico San Cecilio /ID# 272665Granada, SpainContact: Shari ChapmanTaking people
- Hospital Universitario Virgen de las Nieves /ID# 275741Granada, SpainContact: Shari ChapmanTaking people
- Hospital Juan Ramón Jiménez /ID# 272667Huelva, SpainContact: Shari ChapmanTaking people
- Hospital Rafael Mendez /ID# 272663Lorca, SpainContact: Shari ChapmanTaking people
- Hospital Universitario 12 de Octubre /ID# 272660Madrid, SpainContact: Shari ChapmanTaking people
- Hospital Universitario de La Princesa /ID# 264073Madrid, SpainContact: Shari ChapmanTaking people
- Hospital Universitario La Paz /ID# 264316Madrid, SpainContact: Shari ChapmanTaking people
- Hospital Universitario Virgen de la Victoria /ID# 264317Málaga, SpainContact: Shari ChapmanTaking people
- Hospital General Universitario Reina Sofía /ID# 272664Murcia, SpainContact: Shari ChapmanTaking people
- Hospital Universitario de Valme /ID# 264314Seville, SpainContact: Shari ChapmanTaking people
- Hospital Xeral Cies (CHUVI) /ID# 272659Vigo, SpainContact: Shari ChapmanTaking people
About the trial
What the trial wants to find out
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Read full original descriptionShow less
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
The 2 groups in the trial
- Biologic Disease-Modifying Antirheumatic Drugs (bDMARD)
Participants will receive bDMARDs as prescribed by their physician according to local label.
- Risankizumab
Participants will receive risankizumab as prescribed by their physician according to local label.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
- Plain-language title
- Follows adults with psoriatic arthritis treated with risankizumab over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06764693, who can take part
- Record updated
- 17 February 2026